Explore
Validate
Learn
Western blot
Other assayAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-69480 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- LBX2 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- This target displays homology in the following species: Human: 100%; Pig: 75%
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Concentration
- 0.5 mg/mL
- Storage
- -20° C, Avoid Freeze/Thaw Cycles
Submitted references Identification of LBX2 as a novel causal gene of lung adenocarcinoma.
Hu J, Bai Y, Zhang Q, Li M, Yin R, Xu L
Thoracic cancer 2020 Aug;11(8):2137-2145
Thoracic cancer 2020 Aug;11(8):2137-2145
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 6 LBX2 might regulate EMT progression, leading to increased cell proliferation, migration and invasion of LUAD. ( a ) GSEA analysis revealed that LBX2 expression was highly correlated with EMT process ( ) Enrichment profile, ( ) Hits, ( ) Ranking metric scores. ( b ) Western blot showed that knockdown of LBX2 increased the expression of E-cadherin and decreased the expression of N-cadherin and vimentin, and ectopic expression of LBX2 showed the reverse effect.
